Loading company
$6.68-12.5%Nov 13 close
Figures through July 31, 2026, from the 10-Q filed September 14, 2026
Past performance
- 1W
- -2.3%
- 1M
- +0.9%
- 3M
- -36.2%
- 6M
- -63.0%
- 1Y
- -55.3%
- 5Y
- -87.5%
$6.68-12.5%Nov 13 close
Figures through July 31, 2026, from the 10-Q filed September 14, 2026
The quarter ending July 31, 2026, against the same quarter a year earlier.
| Measure | 3 months toJul 31, 2026 | 3 months toJul 31, 2025 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | — |
| Profit | -$5.1M | -$8.4M | +39.22% |
| Profit per share | -$0.54 | -$1.23 | +56.10% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
PharmaCyte Biotech, Inc. has no earnings call transcript available.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
The quote and the company description come from PharmaCyte Biotech, Inc.’s Item 2.02 8-K filed July 11, 2022; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.